Unrecognized Drug Interaction: Ranolazine Adverse Effects Intensified by Darunavir-Cobicistat

Abstract

Get full access to this article

View all access options for this article.

References

Darunavir-cobicistat (Prezcobix^®) [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/PREZCOBIX-pi.pdf. Accessed February 12, 2019.

Ranolazine (Ranexa^®) [package insert]. Foster City, CA: Gilead Sciences, Inc.; https://www.ranexahcp.com. Accessed February 12, 2019.

Naranjo

Busto

Sellers

et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.

Ranolazine Clinical Pharmacology and Biopharmaceutics Review. NDA 21526 S-004. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021526Orig1s004ClinPharmR.pdf. Accessed February 12, 2019.

Mezincescu

Karthikeyan

Nadar

SK.

Ranolazine: a true pluripotent cardiovascular drug or jack of all trades, master of none?

Sultan Qaboos Univ Med J. 2018;18:e13-e23. doi:10.18295/squmj.2018.18.01.003

Jerling

Juan

B-L

Leung

et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45:422-433. doi:10.1177/0091270004273992